В статье рассмотрены эпидемиология, факторы риска, патофизиологические механизмы повреждения головного мозга и дифференцированные подходы к ведению пациентов с церебральным инсультом. Наиболее оптимальной является система этапной помощи, которая включает: догоспитальный этап, этап интенсивной терапии, этап восстановительного лечения и диспансерный этап. Ключевые слова: инсульт, ишемический инсульт, геморрагический инсульт, лечение инсульта, церебральный инсульт, этапная помощь при инсульте.
________________________________________________
The article describes the epidemiology, risk factors, pathophysiological mechanisms of brain damage and differentiated approaches to the management of patients with cerebral stroke. Optimal system is a landmark assistance, which includes: prehospital phase of intensive care, rehabilitation treatment stage and dispensary stage. Key words: stroke, ischemic stroke, hemorrhagic stroke, treatment of stroke, cerebral stroke, stages of stroke care.
1. Клочихина О.А., Стаховская Л.В. Анализ эпидемиологических показателей инсульта по данным территориально-популяционных регистров 2009–2012 гг. Журн. неврологии и психиатрии им. С.С.Корсакова. 2014; 114 (6): 63–9.
2. Фейгин В.Л., Никитин Ю.П., Виберс Д.О. Эпидемиология инсульта в Сибири. Журн. неврологии и психиатрии им. С.С.Корсакова. 2001; 101 (1): 52–7.
3. Feigin VL, Nikitin YP. Seasonal variation in the occurrence of ischemic stroke and subarachnoid hemorrhage in Siberia, Russia. A population-based study. Eur J Neurol 1998; 5 (1): 23–7.
4. Feigin VL, Nikitin YP, Bots ML et al. A population-based study of the associations of stroke occurrence with weather parameters in Siberia, Russia (1982–92). Eur J Neurol 2000; 7 (2): 171–8.
5. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002–2012 гг. Вестн. Российской академии медицинских наук. 2013; 2: 4–11.
6. Whisnant J. Modeling of risk factors for ischemic stroke. The Willis lecture. Stroke 1997; 28: 1839–43.
7. Flossmann E, Schulz UGR, Rothwell PM. A systematic review of the methods and results of studies of the genetic epidemiology of ischaemic stroke. Stroke 2004; 35: 212–27.
8. Парфенов М.Г., Титов Б.В., Мартынов М.Ю. и др. Комплексный анализ генетической предрасположенности к ишемическому инсульту у русских. Молекулярная биология. 2009; 43: 937–45.
9. Heiss WD. The ischemic penumbra: how does tissue injury evolve? Ann NY Acad Sci 2012; 1268: 26–34.
10. Heiss WD, Kracht LW, Thiel A et al. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001; 124
(Pt. 1): 20–9.
11. Del Bigio MR, Yan HJ, Buist R, Peeling J. Experimental intracerebral hemorrhage in rats. Magnetic resonance imaging and histopathological correlates. Stroke 1996; 27: 2312–9.
12. Стоник В.А., Гусев Е.И., Мартынов М.Ю. и др. Поиск веществ для лечения геморрагического инсульта: использование МРТ в оценке эффективности гистохрома. Доклады Российской академии наук. 2005; 45: 51–3.
13. Wu J, Hua Y, Keep RF et al. Oxidative brain injury from extravasated erythrocytes after intracerebral hemorrhage. Brain Res 2002; 953 (1–2): 45–52.
14. Xi G, Keep RF, Hoff JT. Pathophysiology of brain edema formation. Neurosurg Clin N Am 2002; 13: 371–83.
15. Enzmann DR, Britt RH, Lyons BE et al. Natural history of experimental intracerebral hemorrhage: sonography, computed tomography and neuropathology. AJNR Am J Neuroradiol 1981; 2 (6): 517–26.
16. Lee KR, Betz AL, Kim S et al. The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage. Acta Neurochir (Wien) 1996; 138 (4): 396–400.
17. Gebel JM, Brott TG, Sila CA. Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage. Stroke 2000; 31: 596–600.
18. Lee KR, Kawai N, Kim S et al. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg 1997; 86 (2): 272–8.
19. Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989; 1 (3): 165–211.
20. Гусев Е.И. Ишемическая болезнь головного мозга. Актовая речь. М., 1992.
21. Боголепов Н.К. Церебральные кризы и инсульт. М.: Медицина, 1971.
22. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.
23. Trouillas P, Nighoghossian N, Getenet JC et al. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Stroke 1996; 27 (5): 882–90.
24. Jr Haley EC, Levy DE, Brott TG et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 1992; 23 (5): 641–5.
25. Keris V, Rudnicka S, Vorona V et al. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 2001; 22 (2): 352–8.
26. Wolfe T, Suarez JI, Tarr RW et al. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
J Stroke Cerebrovasc Dis 2008; 17 (3): 121–8.
27. The National Institute of Neurological Disorders and Stroke t-PA Study Group. N Engl J Med 1995; 333: 1581–7.
28. Coull BM, Williams LS, Goldstein LB et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002; 33: 1934–42.
29. Teernstra OP, Evers SM, Lodder J et al. Multicenter randomized controlled trial (SICHPA) Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA). Stroke 2003; 34 (4): 968–74.
30. Mendelow AD, Gregson BA, Fernandes HM et al. STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365 (9457): 387–97.
31. Lyden P, Shin C, Jackson-Friedman C et al. Effect of Ganaxolone in a rodent model of cerebral hematoma. Stroke 2000; 31: 169–74.
32. Nakamura T, Keep RF, Hua Y et al. Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Neurosurg Focus 2003; 15 (4): 4–10.
33. Wahlgren N, Díez-Tejedor E, Teitelbaum J et al. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of Clomethiazole versus placebo in acute stroke patients. Stroke 2000; 31: 82–9.
34. Мищенко Н.П., Федореев С.А., Багирова В.Л. Новый оригинальный отечественный препарат гистохром. Хим.-фармацевт. журн. 2003; 37 (1): 49–53.
35. Богуславская Л.В., Храпова Н.Г., Максимов О.Б. Полигидроксинафтохиноны – новый класс природных антиоксидантов. Изв. АН СССР. Сер. хим. 1985; 7: 1471–6.
36. Гусев Е.И., Стоник В.А., Мартынов М.Ю. и др. Влияние гистохрома на динамику неврологических нарушений и МРТ-изменения при экспериментальном геморрагическом инсульте. Журн. неврологии и психиатрии им. С.С.Корсакова. 2005;
105 (15): 61–6.
37. Jauch EC, Saver JL, Adams HP et al. American Heart Association Stroke Council; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44 (3): 870–947.
38. Hill MD, Muir KW. INTERACT-2: should blood pressure be aggressively lowered acutely after intracerebral hemorrhage? Stroke 2013; 44 (10): 2951–2.
39. Qureshi AI, Palesch YY, Martin R et al. Interpretation and Implementation of Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT II). J Vasc Interv Neurol 2014; 7 (2): 34–40.
40. Liu H, Song L, Zhang T. Changes in brain activation in stroke patients after mental practice and physical exercise: a functional MRI study. Neural Regan Res 2014; 9 (15): 1474–84.
41. Dijkhuizen RM, Van der Marel K, Otte WM et al. Functional MRI and diffusion tensor imaging of brain reorganization after experimental stroke. Transl Stroke Res 2012; 3 (1): 36–43.
42. Borlongan CV. Cell therapy for stroke: remaining issues to address before embarking on clinical trials. Stroke 2009; 40 (Suppl.): S146–8.
43. Savitz SI, Cramer SC, Wechsler L. STEPS 3 Consortium. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. Stroke 2014; 45 (2): 634–9.
44. Lindgren A Stroke genetics: a review and update. Stroke 2014;
16 (3): 114–23.
45. Munshi A, Sharma V. Genetic signatures in the treatment of stroke. Curr Pharm Des 2014; 21 (3): 343–54.